Mefloquine [WR 142,490; a-(2-piperidyl)-2,8-bis(trifluoromethyl)-4-quinolinemethanol] is a new antimalarial drug (18) that is effective in the treatment of chloroquine-resistant malaria (21).
It is a quinoline derivative, as is chloroquine, but it is more hydrophobic than chloroquine. Because both are quinoline derivatives, the possibility has been considered that the chemotherapeutic effects of mefloquine and chloroquine are mediated through identical receptors (8). Consistent with this possibility, mefloquine is a competitive inhibitor of chloroquine binding in erythrocytes infected with Plasmodium berghei (7), and chloroquine is a competitive inhibitor of mefloquine binding (8) . Against the possibility of identical receptors are the following observations. The capacity of infected and uninfected erythrocytes to bind mefloquine with high affinity greatly exceeds the capacity to bind chloroquine with high affinity (6, 8) . The apparent Ki of chloroquine as a competitive inhibitor of mefloquine binding is several orders of magnitude higher than the apparent Kd for chloroquine binding to its receptor, 10-3 M versus 10-8 M (6, 8). Erythrocytes infected with chloroquine-resistant malaria parasites accumulate less chloroquine than erythrocytes infected with chloroquine-susceptible malaria parasites (6, 11), whereas chloroquine resistance has no appreciable effect on mefloquine accumulation (8). Also, the process of chloroquine accumulation by erythrocytes infected with chloroquine-suscepti-ble P. berghei requires energy (11), whereas the accumulation of mefloquine apparently does not (8). These observations could be explained if mefloquine has greater access than chloroquine to identical receptors (8), but they also could be explained by the existence of a second receptor for mefloquine. The high-affinity receptor for chloroquine in erythrocytes infected with malaria parasites is ferriprotoporphyrin IX (FP) (3, 9, 19). We now present evidence that mefloquine interacts strongly both with FP and with certain phospholipids.
MATERIALS AND METHODS
Male Swiss-Webster mice weighing approximately 20 g were purchased from Hilltop Laboratories for use as donors of erythrocytes. For some of the experiments, groups of mice were infected either with chloroquine-resistant or with chloroquine-susceptible P. berghei of the NYU-2 strain. These two lines of parasites have been described in detail previously (6, 11) . To prepare membranes, heparinized blood was pooled from groups of mice and washed twice (6, 10) with an isotonic medium (10) buffered to pH 7.4 with 50 mM phosphate (standard medium). As much as possible of the buffy coat was discarded with each wash. After washing, a 50% suspension of erythrocytes in the standard medium was cooled to 4°C and lysed by mixing with 20 volumes of cold, distilled water buffered to pH 8 with 5 mM phosphate. The hemolysate then was centrifuged at 27,000 x g for 15 min at 4°C, after which the supematant solution was discarded. The membrane pellets were washed twice by resuspending them in the same volume of 5 mM phosphate used initially and centrifuging again. Lipids were obtained from these membrane preparations by chloroform-methanol extraction (2) and quantitated concentrations by previously described methods (6, 8). The recovery of drug in these experiments exceeded 90%o of the amounts added at the beginning of dialysis.
A nonspecific protease from Streptomyces griseus (type VI), phospholipase C from Bacillus cereus (type V), and purified phospholipids were obtained from Sigma Chemical Co. The L-a-phosphatidylcholine was from egg yolk (type IX-E), the L-CX-phosphatidylinositol was from soybeans (grade I), and the L-a-phosphatidyl-L-serine was from bovine brain. (Fig. 1) , the of Fig. 2 ).
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In agreement with the effect of phospholipase ictropor 3 mem-C, mefloquine binding to lipids extracted from ies, Inc.) with a normal erythrocyte membranes was easily demmembranes were onstrated (Fig. 3) . For comparison, studies of )nized, twice-dis-lipids from erythrocytes infected either with wed by thorough chloroquine-susceptible or with chloroquine-red for 65 to 70 h at sistant P. berghei also are shown in Fig. 3 (22) were suspended at a concentration of 1.7 mg of protein per ml in standard medium, pH 7.4. This suspension was incubated with or without 2.8 mg of a nonspecific protease from S. griseus per ml for 60 min at 37°C. Then the incubation mixtures were centrifuged at 5,000 x g, and the supematant solutions were removed and replaced with fresh standard medium. After mixing, mefloquine binding to the pellets was measured by equilibrium dialysis. The nanomoles of mefloquine bound per 5-ml dialysis bag are shown on the ordinate. Symbols: (0) With protease; (0) without protease. (Upper panel) Stripped membranes were suspended at a concentration of 1.25 mg of protein per ml and incubated with or without 80 U of phospholipase C per ml for 60 min at 37°C, using a medium composed of 0.1 M Tris, 10 mM calcium chloride, and 0.25 ml of glycerol per ml. After incubation, the membrane pellets were recovered by centrifuging at 27,000 x g for 15 min at 4°C and washed twice by suspending them in ice-cold distilled water equal in volume to the initial incubation volume and centrifuging again. The washed pellets were suspended in standard medium equal in volume to the initial incubation volume for measurement of mefloquine binding by equilibrium dialysis. The nanomoles of mefloquine bound per 5-ml dialysis bag are shown on the ordinate. Because phospholipids account for much of the total lipid of biological membranes, purified phospholipids were studied next. The capacities of phosphatidylinositol and phosphatidylserine to bind mefloquine with high affinity were 300 to 400 nmollmg and were much greater than the capacity of phosphatidylcholine (-100 nmoll mg), but all three phospholipids had similar affinities for the drug (Fig. 4) . The apparent Kd was 3 x 10-7 M. In other experiments (not shown), mefloquine binding to phosphatidylethanolamine was similar to the binding to phosphatidylcholine, but little or no high-affinity binding of mefloquine to phosphatidic acid or to sphingomyelin was detected. In addition to binding to phospholipids, mefloquine bound with high affinity to the chloroquine receptor FP (Fig. 6) . In fact, the apparent Kd for binding to FP was indistinguishable from the Kd for binding to erythrocyte membrane lipids (-3 X 1o-7 M). For comparison, chloroquine bound to pure FP with a Kd of 3.5 x 1O-9 M (3).
DISCUSSION
Cationic, amphiphilic drugs such as chloroquine are known to concentrate in lysosomes (1, 5) and to cause the accumulation of phospholipids in these organelles (14, 23). In particular, there is an increase in acidic phospholipids, including phosphatidylinositol and bis(monoacylglycerol) phosphate (17, 24) . Associated with drug and phospholipid accumulation is inhibition of lysosomal phospholipases A and C (16), possibly because the drugs bind to phospholipids and make them inaccessible as substrates. The extensive high-affinity binding of mefloquine to phospholipids described here is of interest, therefore, not only because it may lead to an understanding of the mode of action of the drug but also because it may provide a useful model for study of the interaction of amphiphilic drugs with membrane phospholipids. Ionic attractions and lipid solubility apparently are involved (12, 15). Otherwise, the interactions are incompletely understood, and they may be different for intact biological membranes than for phospholipids dispersed in the form of liposomes (4). In addition to providing a promising model for study of drug-phospholipid interactions, knowing that mefloquine binds with high affinity to phospholipids as well as to FP helps explain why this drug behaves differently from chloroquine in biological systems. Clearly, the large accumulation of mefloquine and the lack of a difference between chloroquine-susceptible and chloroquine-resistant P. berghei with respect to mefloquine accumulation are attributable to binding to phospholipids. Furthermore, the lack of an energy requirement to bind large amounts of mefloquine to phospholipids may obscure an energy requirement for the binding of relatively small amounts of mefloquine to FP. Thus, an energy requirement to make FP accessible to mefloquine in malaria parasites could go undetected. 
